Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05317416 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05317416 · ClinicalTrials.gov record · last posted 2026-04-16

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Study acronym: MagnetisMM-7
StatusActive, Not Recruiting
PhasePhase 3
SponsorPfizer
Started2022-03-25
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years

Amendment record 77 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 77 times since 2022-03-30; most recent amendment 2026-04-13. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-12-18
Status change Recruiting→Active, Not Recruitingv76
Trial Details
NCT Number NCT05317416
Lead Sponsor Pfizer
Conditions Multiple Myeloma
Enrollment 854 participants
Start Date 2022-03-25
Primary Completion 2027-08-04 (estimated)
Study Completion 2029-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-16